Prediction of hepatic and intestinal glucuronidation using in vitro-in vivo extrapolation

Drug Metabolism and Pharmacokinetics

Volumn 30, Issue 1, 2015, Pages 21-29

  Naritomi, Yoichi ^a   Nakamori, Fumihiro ^a   Furukawa, Takako ^a   Tabata, Kenji ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Availability; Clearance Prediction; Glucuronidation; In vitro in vivo extrapolation; Intestine; Liver; UDP glucuronosyltransferase

Indexed keywords

GLUCURONOSYLTRANSFERASE; DRUG; GLUCURONIDE; ISOENZYME;

ARTICLE; ENZYME KINETICS; GLUCURONIDATION; HUMAN; IN VITRO IN VIVO EXTRAPOLATION; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; INTRINSIC CLEARANCE; INVESTIGATIVE PROCEDURES; LIVER CELL; LIVER MICROSOME; NONHUMAN; PREDICTION; ANIMAL; BIOLOGICAL MODEL; ENZYME SPECIFICITY; ENZYMOLOGY; INTESTINE; LIVER; METABOLISM; MICROSOME; PHARMACOKINETICS; PREDICTIVE VALUE; SPECIES DIFFERENCE;

ANIMALS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HEPATOCYTES; HUMANS; IN VITRO TECHNIQUES; INTESTINES; ISOENZYMES; LIVER; MICROSOMES; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PREDICTIVE VALUE OF TESTS; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY;

EID: 84924967299     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.1016/j.dmpk.2014.10.001     Document Type: Review

References (63)

1. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3 2004 711 715
2. T. Iwatsubo, N. Hirota, T. Ooie, H. Suzuki, N. Shimada, and K. Chiba Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data Pharmacol Ther 73 1997 147 171
3. J.C. Kolars, W.M. Awni, R.M. Merion, and P.B. Watkins First-pass metabolism of cyclosporin by the gut Lancet 338 1991 1488 1490
4. M.F. Paine, D.D. Shen, K.L. Kunze, J.D. Perkins, C.L. Marsh, and J.P. McVicar First-pass metabolism of midazolam by the human intestine Clin Pharmacol Ther 60 1996 14 24
5. R.S. Obach Predicting clearance in humans from in vitro data Curr Top Med Chem 11 2011 334 339
6. T. Akabane, N. Gerst, Y. Naritomi, J.N. Masters, and K. Tamura A practical and direct comparison of intrinsic metabolic clearance of several non-CYP enzyme substrates in freshly isolated and cryopreserved hepatocytes Drug Metab Pharmacokinet 27 2012 181 191
7. T. Mizuma Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10 Int J Pharm 378 2009 140 141
8. K. Kadono, T. Akabane, K. Tabata, K. Gato, S. Terashita, and T. Teramura Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor Drug Metab Dispos 38 2010 1230 1237
9. J.A. Williams, R. Hyland, B.C. Jones, D.A. Smith, S. Hurst, and T.C. Goosen Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios Drug Metab Dispos 32 2004 1201 1208
10. J.H. Lin, and B.K. Wong Complexities of glucuronidation affecting in vitro in vivo extrapolation Curr Drug Metab 3 2002 623 646
11. J.O. Miners, P.A. Smith, M.J. Sorich, R.A. McKinnon, and P.I. Mackenzie Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches Annu Rev Pharmacol Toxicol 44 2004 1 25
12. J.O. Miners, K.M. Knights, J.B. Houston, and P.I. Mackenzie In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises Biochem Pharmacol 71 2006 1531 1539
13. J.K. Ritter Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics Expert Opin Drug Metab Toxicol 3 2007 93 107
14. J.O. Miners, P.I. Mackenzie, and K.M. Knights The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential Drug Metab Rev 42 2010 196 208
15. B. Wu, D. Dong, M. Hu, and S. Zhang Quantitative prediction of glucuronidation in humans using the in vitro- in vivo extrapolation approach Curr Top Med Chem 13 2013 1343 1352
16. G. Bánhegyi, T. Garzó, R. Fulceri, A. Benedetti, and J. Mandl Latency is the major determinant of UDP-glucuronosyltransferase activity in isolated hepatocytes FEBS Lett 328 1993 149 152
17. R.H. Tukey, and C.P. Strassburg Human UDP-glucuronosyltransferases: metabolism, expression, and disease Annu Rev Pharmacol Toxicol 40 2000 581 616
18. P.I. Mackenzie, K.W. Bock, B. Burchell, C. Guillemette, S. Ikushiro, and T. Iyanagi Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily Pharmacogenet. Genomics. 15 2005 677 685
19. S. Ohno, and S. Nakajin Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction Drug Metab Dispos 37 2009 32 40
20. Y. Sato, M. Nagata, K. Tetsuka, K. Tamura, A. Miyashita, and A. Kawamura Optimized methods for targeted peptide-based quantification of human uridine 5'-diphosphate-glucuronosyltransferases in biological specimens using liquid chromatography-tandem mass spectrometry Drug Metab Dispos 42 2014 885 889
21. J.K. Fallon, H. Neubert, R. Hyland, T.C. Goosen, and P.C. Smith Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring J Proteome Res 12 2013 4402 4413
22. D.E. Harbourt, J.K. Fallon, S. Ito, T. Baba, J.K. Ritter, and G.L. Glish Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry Anal Chem 84 2012 98 105
23. J.B. Houston, and A. Galetin Modelling atypical CYP3A4 kinetics: principles and pragmatism Arch Biochem Biophys 433 2005 351 360
24. Y. Naritomi, S. Terashita, S. Kimura, A. Suzuki, A. Kagayama, and Y. Sugiyama Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans Drug Metab Dispos 29 2001 1316 1324
25. L. Di, P. Trapa, R.S. Obach, K. Atkinson, Y.A. Bi, and A.C. Wolford A novel relay method for determining low-clearance values Drug Metab Dispos 40 2012 1860 1865
26. A. Rane, G.R. Wilkinson, and D.G. Shand Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance J Pharmacol Exp Ther 200 1977 420 424
27. K.S. Pang, and M. Rowland Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance J Pharmacokinet Biopharm 5 1977 625 653
28. M.S. Roberts, and M. Rowland Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model J Pharm Pharmacol 38 1986 177 181
29. J.J. Bouska, R.L. Bell, C.L. Goodfellow, A.O. Stewart, C.D. Brooks, and G.W. Carter Improving the in vivo duration of 5-lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay Drug Metab Dispos 25 1997 1032 1038
30. M. Mistry, and J.B. Houston Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine Drug Metab Dispos 15 1987 710 717
31. T. Izumi, K. Hosiyama, S. Enomoto, K. Sasahara, and Y. Sugiyama Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data J Pharmacol Exp Ther 280 1997 1392 1400
32. S. Uno, A. Fujii, H. Komura, A. Kawase, and M. Iwaki Prediction of metabolic clearance of diclofenac in adjuvant-induced arthritis rats using a substrate depletion assay Xenobiotica 38 2008 482 495
33. F. Nakamori, Y. Naritomi, M. Furutani, F. Takamura, H. Miura, and H. Murai Correlation of intrinsic in vitro and in vivo clearance for drugs metabolized by hepatic UDP-glucuronosyltransferases in rats Drug Metab Pharmacokinet 26 2011 465 473
34. M.B. Fisher, K. Campanale, B.L. Ackermann, M. VandenBranden, and S.A. Wrighton In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin Drug Metab Dispos 28 2000 560 566
35. S. Kumar, K. Samuel, R. Subramanian, M.P. Braun, R.A. Stearns, and S.H. Chiu Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide J Pharmacol Exp Ther 303 2002 969 978
36. M.G. Soars, B.J. Ring, and S.A. Wrighton The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases Drug Metab Dispos 31 2003 762 767
37. N. Ishiguro, K. Maeda, W. Kishimoto, A. Saito, A. Harada, and T. Ebner Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans Drug Metab Dispos 34 2006 1109 1115
38. A. Rowland, P. Gaganis, D.J. Elliot, P.I. Mackenzie, K.M. Knights, and J.O. Miners Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation J Pharmacol Exp Ther 321 2007 137 147
39. S. Boase, and J.O. Miners In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine Br J Clin Pharmacol 54 2002 493 503
40. M.G. Soars, B. Burchell, and R.J. Riley In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance J Pharmacol Exp Ther 301 2002 382 390
41. K.F. Ilett, B.T. Ethell, J.L. Maggs, T.M. Davis, K.T. Batty, and B. Burchell Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases Drug Metab Dispos 30 2002 1005 1012
42. J.J. Engtrakul, R.S. Foti, T.J. Strelevitz, and M.B. Fisher Altered AZT (3′-azido-3'-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment Drug Metab Dispos 33 2005 1621 1627
43. P. Tsoutsikos, J.O. Miners, A. Stapleton, A. Thomas, B.C. Sallustio, and K.M. Knights Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7 Biochem Pharmacol 67 2004 191 199
44. A. Rowland, K.M. Knights, P.I. Mackenzie, and J.O. Miners The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities Drug Metab Dispos 36 2008 1056 1062
45. A. Rowland, K.M. Knights, P.I. Mackenzie, and J.O. Miners Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters Drug Metab Dispos 37 2009 1395 1403
46. N. Manevski, P.S. Moreolo, J. Yli-Kauhaluoma, and M. Finel Bovine serum albumin decreases Km values of human UDP-glucuronosyltransferases 1A9 and 2B7 and increases Vmax values of UGT1A9 Drug Metab Dispos 39 2011 2117 2129
47. P.J. Kilford, R. Stringer, B. Sohal, J.B. Houston, and A. Galetin Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes Drug Metab Dispos 37 2009 82 89
48. H.E. Cubitt, J.B. Houston, and A. Galetin Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data Drug Metab Dispos 39 2011 864 873
49. R.K. Kuester, and I.G. Sipes Prediction of metabolic clearance of bisphenol A (4,4 '-dihydroxy-2,2-diphenylpropane) using cryopreserved human hepatocytes Drug Metab Dispos 35 2007 1910 1915
50. W.S. Al-Jahdari, K. Yamamoto, H. Hiraoka, K. Nakamura, F. Goto, and R. Horiuchi Prediction of total propofol clearance based on enzyme activities in microsomes from human kidney and liver Eur J Clin Pharmacol 62 2006 527 533
51. K.L. Gill, J.B. Houston, and A. Galetin Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin Drug Metab Dispos 40 2012 825 835
52. K.L. Gill, M. Gertz, J.B. Houston, and A. Galetin Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data Drug Metab Dispos 41 2013 744 753
53. C.R. Gibson, P. Lu, C. Maciolek, C. Wudarski, Z. Barter, and K. Rowland-Yeo Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans Xenobiotica 43 2013 1027 1036
54. J. Yang, M. Jamei, K.R. Yeo, G.T. Tucker, and A. Rostami-Hodjegan Prediction of intestinal first-pass drug metabolism Curr Drug Metab 8 2007 676 684
55. M. Gertz, A. Harrison, J.B. Houston, and A. Galetin Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data Drug Metab Dispos 38 2010 1147 1158
56. H. Nishimuta, K. Sato, M. Yabuki, and S. Komuro Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data Drug Metab Pharmacokinet 26 2011 592 601
57. T. Furukawa, K. Yamano, Y. Naritomi, K. Tanaka, S. Terashita, and T. Teramura Method for predicting human intestinal first-pass metabolism of UGT substrate compounds Xenobiotica 42 2012 980 988
58. T. Furukawa, F. Nakamori, K. Tetsuka, Y. Naritomi, H. Moriguchi, and K. Yamano Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data Drug Metab Pharmacokinet 27 2012 171 180
59. M.K. Shelby, N.J. Cherrington, N.R. Vansell, and C.D. Klaassen Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family Drug Metab Dispos 31 2003 326 333
60. M. Nishimura, A. Koeda, H. Morikawa, T. Satoh, S. Narimatsu, and S. Naito Tissue-specific mRNA expression profiles of drug-metabolizing enzymes and transporters in the cynomolgus monkey Drug Metab Pharmacokinet 24 2009 139 144
61. F. Nakamori, Y. Naritomi, K. Hosoya, H. Moriguchi, K. Tetsuka, and T. Furukawa Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data Drug Metab Dispos 40 2012 1771 1777
62. H. Komura, and M. Iwaki In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences Drug Metab Rev 43 2011 476 498
63. T. Furukawa, Y. Naritomi, K. Tetsuka, F. Nakamori, H. Moriguchi, and K. Yamano Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys Xenobiotica 44 2014 205 216